NeoGenomics, Inc. — FY 2011 Form 10-K
Business context and reporting period
The filing reports the fiscal year ended December 31, 2011, with 2010 as the comparable year. It is an annual report, not a standalone Q4 report; the supplied filing text does not provide clear Q4-only financial results. NeoGenomics operates U.S. cancer-focused clinical laboratories offering cytogenetics, FISH, flow cytometry, immunohistochemistry, and molecular testing.
Financial and operating performance
| Metric | FY 2011 | FY 2010 |
|---|---|---|
| Revenue | $43.484 million | $34.371 million |
| Gross profit / margin | $19.428 million / 44.7% | $15.783 million / 45.9% |
| Operating loss | $0.409 million | $2.963 million |
| Net loss | $1.177 million; $0.03 per share | $3.303 million; $0.09 per share |
| Adjusted EBITDA (non-GAAP) | $2.134 million | $(0.566) million |
| Cash from operations | $0.069 million | $(2.052) million |
- Requisitions grew 28.1% to 49,235 and tests performed grew 33.1% to 76,288. Average revenue per test fell 4.9% to $570.
- At December 31, 2011, cash and cash equivalents were $2.628 million, restricted cash was $0.500 million, and working capital was $1.734 million. Total assets were $19.949 million.
- Debt-like obligations included a $3.898 million revolving credit balance and $4.715 million in capital lease obligations. The company reported approximately $1.1 million available under its $5 million CapitalSource facility and said it was covenant-compliant.
- Gross accounts receivable were $10.044 million, with a $2.150 million doubtful-account allowance; net receivables were $7.894 million. Gross receivables over 120 days totaled $2.841 million.
Changes versus FY 2010
- Revenue rose 26.5%, driven by new clients and deeper penetration of existing accounts, while tests per requisition increased 4.0%.
- Gross margin declined 1.2 percentage points. Management attributed pressure mainly to lower reimbursement per test; laboratory productivity reduced cost per test 2.7%.
- Sales and marketing expense declined 6.9% to $6.963 million, while general and administrative expense increased 14.3% to $12.874 million. Bad-debt expense rose, but declined as a share of revenue to 5.90% from 6.56%.
- Net loss narrowed by $2.126 million. Operating cash flow improved from a $2.052 million use to $0.069 million provided, but remained modest.
Outlook, risks, and unusual items
- Management expected positive operating cash flow in 2012 and believed resources were adequate for the next year, while noting that additional financing might be needed if cash generation or borrowing capacity proved insufficient.
- The company forecast $4–5 million of capital equipment purchases over the next year and anticipated higher investment in facilities, backup systems, billing, collections, and research and development. It expected operating leverage to lower G&A as a share of revenue over time.
- Reimbursement changes had already reduced average revenue per test: bladder-cancer FISH reimbursement fell about 50%; Medicare clinical lab fee schedule rates fell 1.75%; and allowable flow-cytometry markers were reduced in some regions. Medicare and other government payers accounted for 43% of revenue.
- Major risks include further reimbursement or coverage cuts, complex healthcare billing and regulatory compliance, possible LDT oversight changes, reliance on Abbott for most FISH probes, competition, growth and capacity execution, payer collections, and reliance on FedEx for specimen transport. The company also disclosed no backup generator at its Nashville or Irvine laboratory.
- In January 2012, the company entered an exclusive worldwide license with Health Discovery Corporation (HDC), paying $1 million cash and issuing 1.36 million shares. The agreement includes potential milestone payments of up to $5 million and royalties under specified revenue thresholds and terms; initial development targets include prostate, colon, and pancreatic cancer tests and interpretation software.
- The IRS notified the company in January 2012 of audits of its 2009 and 2010 tax returns; the review was preliminary and its impact was unknown. The company also acquired certain Power3 intellectual property in March 2012 after a judgment remained unpaid.
- The independent auditor issued an unqualified opinion on the financial statements. The auditor did not attest to internal control over financial reporting; management concluded controls were effective.
Important facts for investors to verify
- Whether 2012 operating cash flow can fund planned $4–5 million capital expenditures and ongoing growth without additional financing or equity issuance.
- Receivables aging, collection performance, and the adequacy of revenue and bad-debt estimates, particularly for non-contracted payers.
- Effects of reimbursement and coverage changes, including the expiration or phase-out of Medicare technical-component grandfathering provisions described in the filing.
- CapitalSource covenant compliance, borrowing availability, repayment terms, and capital lease obligations.
- HDC license commercialization milestones, the cost and dilution from the transaction, and the revenue and royalty provisions.
- Results of the IRS audits and any resulting tax exposure; also monitor the company’s dependence on Abbott FISH probes and specimen-shipping continuity.